Legend Biotech (LEGN) is back in focus after early Phase 1 results for LB2501, its in vivo CD19/CD20 CAR-T candidate, showed a 100% response rate and favorable safety at the higher dose in difficult to treat lymphoma.

The LB2501 update comes after a strong run in the stock, with a 7 day share price return of 21.02% and a 90 day share price return of 80.28%. However, the 3 year total shareholder return has declined 50.37%, so recent momentum contrasts with a weaker longer term record.

If you are interested in other fast moving opportunities in healthcare and next generation therapies, this is a good moment to scan 40 healthcare AI stocks

With Legend Biotech shares at US$34.20 and trading at a steep discount to the average analyst price target of US$56.39, the key question now is simple: is this discounted entry or has the market already priced in future growth?

Most Popular Narrative: 40.2% Undervalued

Against the last close at $34.20, the most followed narrative places Legend Biotech's fair value at $57.24, setting a wide valuation gap for investors to assess.

Robust innovation pipeline, including next-generation CAR-Ts and in vivo/off-the-shelf cell therapy technologies (e.g., TaVec platform), positions Legend to capitalize on rising demand for advanced, personalized therapies amid secular increases in cancer incidence and sustained healthcare investment, supporting future revenue streams and risk diversification.

Analysts behind this narrative are not just leaning on one therapy. Their fair value leans heavily on projected revenue expansion, rising margins, and a profit profile that looks very different to today's losses. Curious which assumptions, and how bold they are, sit under that $57.24 figure?

Result: Fair Value of $57.24 (UNDERVALUED)

However, this story can change quickly if execution around Carvykti stumbles or if rival multiple myeloma therapies capture more share than bullish investors expect.

Next Steps

With sentiment clearly split between upside potential and real execution risks, now is a good time to review the underlying data for yourself, weigh the 1 key reward and 1 important warning sign, and decide where you stand.

Looking for more investment ideas?

If Legend Biotech has your attention, do not stop here. Broaden your watchlist with other opportunities that could sharpen your portfolio and highlight fresh angles.

• Spot potential underpriced opportunities quickly by scanning the 47 high quality undervalued stocks and see which stocks the numbers currently favor.
• Strengthen your income stream by reviewing companies in the 10 dividend fortresses that offer higher yields alongside staying power.
• Reduce portfolio stress by focusing on companies in the 65 resilient stocks with low risk scores that score well on resilience and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.